FDA Approves First CRISPR-Based Treatment for Sickle Cell Disease

The FDA has approved exa-cel, a CRISPR-based therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for the treatment of sickle cell disease. This innovative gene editing treatment deactivates the faulty gene responsible for the sickling of red blood cells, thereby reducing the pain and fatigue experienced by patients. Clinical trials have shown that the therapy can prevent the symptoms of the disease for at least one year, with 93.5% of patients remaining free of vaso-occlusive crises during this period.

Approved on December 8, 2023, exa-cel marks a significant milestone in genetic medicine. While the long-term effects of the treatment remain under investigation and its high cost may limit accessibility, this approval represents a promising new direction for the management of sickle cell disease and offers hope to many patients who have struggled with the debilitating effects of the condition.